Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Christopher P. Evans
Observed names:
Christopher P Evans,
Evans, Christopher P
Institutions:
UC Davis Comprehensive Cancer Center,
University of California, Davis
Observed institutions:
University of California Davis Medical Center,
UC Davis Comprehensive Cancer Center,
Istituto Oncologico della Svizzera Italiana,
University of Reading,
University of California, Davis
ORCID:
0000-0003-2419-7592
Observed ORCID:
0000-0003-2419-7592
OpenAlex ID:
A5039925010
Going, Going, Gone? Assessing Iran's Possible Grounds for Withdrawal from the Treaty on the Non-Proliferation of Nuclear Weapons
2021
·
Christopher P. Evans
·
Journal of Conflict and Security Law
·
7
PDF
Transcriptional profiling clarifies a program of enzalutamide extreme non-response in lethal prostate cancer
2025
·
Anbarasu Kumaraswamy
, Ya-Mei Hu
, et al.
·
npj Precision Oncology
·
3
Genitourinary aspects of palliative care
2015
·
Olivia T. Lee
, Jennifer N. Wu
, et al.
·
2
Correction: Novel inhibition of AKR1C3 and androgen receptor axis by PTUPB synergizes enzalutamide treatment in advanced prostate cancer
2025
·
Joy C. Yang
, Pengfei Xu
, et al.
·
Oncogene
·
1
PDF
Metastatic Bone Disease in Kidney Cancer
2024
·
Manolis Pratsinis
, Christopher P. Evans
, et al.
·
Springer eBooks
Data from NF-κB2/p52 Induces Resistance to Enzalutamide in Prostate Cancer: Role of Androgen Receptor and Its Variants
2023
·
Nagalakshmi Nadiminty
, Ramakumar Tummala
, et al.
Data from Whole-Genome and Transcriptional Analysis of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer Demonstrates Intraclass Heterogeneity
2023
·
Rahul R. Aggarwal
, David A. Quigley
, et al.
Supplementary Data from Therapeutic Targeting of MDR1 Expression by RORγ Antagonists Resensitizes Cross-Resistant CRPC to Taxane via Coordinated Induction of Cell Death Programs
2023
·
Yongqiang Wang
, Zenghong Huang
, et al.
PDF
Supplemental Figure S1-S2 from Niclosamide and Bicalutamide Combination Treatment Overcomes Enzalutamide- and Bicalutamide-Resistant Prostate Cancer
2023
·
Chengfei Liu
, Cameron M. Armstrong
, et al.
PDF
Supplementary Figure 1 from NF-κB2/p52 Induces Resistance to Enzalutamide in Prostate Cancer: Role of Androgen Receptor and Its Variants
2023
·
Nagalakshmi Nadiminty
, Ramakumar Tummala
, et al.
Supplementary Figure 2 from NF-κB2/p52 Induces Resistance to Enzalutamide in Prostate Cancer: Role of Androgen Receptor and Its Variants
2023
·
Nagalakshmi Nadiminty
, Ramakumar Tummala
, et al.
Supplementary Figure 6 from NF-κB2/p52:c-Myc:hnRNPA1 Pathway Regulates Expression of Androgen Receptor Splice Variants and Enzalutamide Sensitivity in Prostate Cancer
2023
·
Nagalakshmi Nadiminty
, Ramakumar Tummala
, et al.
Supplemental Figures 1-4 from AKR1C3 Promotes AR-V7 Protein Stabilization and Confers Resistance to AR-Targeted Therapies in Advanced Prostate Cancer
2023
·
Chengfei Liu
, Joy C. Yang
, et al.
Supplementary Figure 1 from Whole-Genome and Transcriptional Analysis of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer Demonstrates Intraclass Heterogeneity
2023
·
Rahul R. Aggarwal
, David A. Quigley
, et al.
PDF
Supplementary Table 2 from Whole-Genome and Transcriptional Analysis of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer Demonstrates Intraclass Heterogeneity
2023
·
Rahul R. Aggarwal
, David A. Quigley
, et al.
Supplementary Figure 3 from NF-κB2/p52:c-Myc:hnRNPA1 Pathway Regulates Expression of Androgen Receptor Splice Variants and Enzalutamide Sensitivity in Prostate Cancer
2023
·
Nagalakshmi Nadiminty
, Ramakumar Tummala
, et al.
Supplementary Figure 4 from NF-κB2/p52:c-Myc:hnRNPA1 Pathway Regulates Expression of Androgen Receptor Splice Variants and Enzalutamide Sensitivity in Prostate Cancer
2023
·
Nagalakshmi Nadiminty
, Ramakumar Tummala
, et al.
Supplementary Figure 5 from NF-κB2/p52:c-Myc:hnRNPA1 Pathway Regulates Expression of Androgen Receptor Splice Variants and Enzalutamide Sensitivity in Prostate Cancer
2023
·
Nagalakshmi Nadiminty
, Ramakumar Tummala
, et al.
Supplementary Figure 1 from NF-κB2/p52:c-Myc:hnRNPA1 Pathway Regulates Expression of Androgen Receptor Splice Variants and Enzalutamide Sensitivity in Prostate Cancer
2023
·
Nagalakshmi Nadiminty
, Ramakumar Tummala
, et al.
Supplementary Figure 4 from NF-κB2/p52:c-Myc:hnRNPA1 Pathway Regulates Expression of Androgen Receptor Splice Variants and Enzalutamide Sensitivity in Prostate Cancer
2023
·
Nagalakshmi Nadiminty
, Ramakumar Tummala
, et al.
Supplemental Figures 1-4 from AKR1C3 Promotes AR-V7 Protein Stabilization and Confers Resistance to AR-Targeted Therapies in Advanced Prostate Cancer
2023
·
Chengfei Liu
, Joy C. Yang
, et al.
PDF
Supplementary Data from Therapeutic Targeting of MDR1 Expression by RORγ Antagonists Resensitizes Cross-Resistant CRPC to Taxane via Coordinated Induction of Cell Death Programs
2023
·
Yongqiang Wang
, Zenghong Huang
, et al.
Supplementary Table 1 from Whole-Genome and Transcriptional Analysis of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer Demonstrates Intraclass Heterogeneity
2023
·
Rahul R. Aggarwal
, David A. Quigley
, et al.
Supplementary Table 2 from Whole-Genome and Transcriptional Analysis of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer Demonstrates Intraclass Heterogeneity
2023
·
Rahul R. Aggarwal
, David A. Quigley
, et al.
Data from NF-κB2/p52:c-Myc:hnRNPA1 Pathway Regulates Expression of Androgen Receptor Splice Variants and Enzalutamide Sensitivity in Prostate Cancer
2023
·
Nagalakshmi Nadiminty
, Ramakumar Tummala
, et al.
Show more works
View as search
Works count:
62
Citation count:
13
H-index:
2
I10-index:
Year
Topic
Type